These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 15167167)
1. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Stallmach A; Giese T; Schmidt C; Meuer SC; Zeuzem SS Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):627-30. PubMed ID: 15167167 [TBL] [Abstract][Full Text] [Related]
2. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease]. Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146 [TBL] [Abstract][Full Text] [Related]
3. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA J Crohns Colitis; 2012 Feb; 6(1):108-11. PubMed ID: 22261535 [TBL] [Abstract][Full Text] [Related]
4. A pilot study of adalimumab in infliximab-allergic patients. Youdim A; Vasiliauskas EA; Targan SR; Papadakis KA; Ippoliti A; Dubinsky MC; Lechago J; Paavola J; Loane J; Lee SK; Gaiennie J; Smith K; Do J; Abreu MT Inflamm Bowel Dis; 2004 Jul; 10(4):333-8. PubMed ID: 15475739 [TBL] [Abstract][Full Text] [Related]
5. Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease. Diamanti A; Castro M; Papadatou B; Ferretti F; Gambarara M J Pediatr; 2002 May; 140(5):636-7; author reply 637. PubMed ID: 12032538 [No Abstract] [Full Text] [Related]
6. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Puchner TC; Kugathasan S; Kelly KJ; Binion DG Inflamm Bowel Dis; 2001 Feb; 7(1):34-7. PubMed ID: 11233658 [TBL] [Abstract][Full Text] [Related]
7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
8. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761 [TBL] [Abstract][Full Text] [Related]
10. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. Cravo M; Silva R; Serrano M BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232 [TBL] [Abstract][Full Text] [Related]
11. Optimizing anti-TNF treatment in inflammatory bowel disease. Rutgeerts P; Van Assche G; Vermeire S Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370 [TBL] [Abstract][Full Text] [Related]
12. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review. Da W; Zhu J; Wang L; Lu Y Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447 [TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Behm BW; Bickston SJ Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120 [TBL] [Abstract][Full Text] [Related]
14. Infliximab in inflammatory bowel disease: attention to adverse events. Uyanikoglu A; Ermis F; Akyuz F; Pinarbasi B; Baran B; Aydogan T; Demir K; Besisik F; Kaymakoglu S Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2337-42. PubMed ID: 25219835 [TBL] [Abstract][Full Text] [Related]
15. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?]. Heidemann J; Kucharzik T Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352 [No Abstract] [Full Text] [Related]
17. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917 [TBL] [Abstract][Full Text] [Related]